Mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África: tendencias de la industria y pronóstico hasta 2029

Solicitud de índiceSolicitud de índice Hable con el analistaHable con el analista Comprar ahoraComprar ahora Consultar antes de comprarConsultar antes Informe de muestra gratuitoInforme de muestra gratuito

Mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África: tendencias de la industria y pronóstico hasta 2029

  • Pharmaceutical
  • Upcoming Report
  • May 2022
  • MEA
  • 350 Páginas
  • Número de tablas: 220
  • Número de figuras: 60

Middle East And Africa Multiple Sclerosis Treatment Market

Tamaño del mercado en miles de millones de dólares

Tasa de crecimiento anual compuesta (CAGR) :  % Diagram

Diagram Período de pronóstico
2022 –2029
Diagram Tamaño del mercado (año base)
USD 235.54 Million
Diagram Tamaño del mercado (año de pronóstico)
USD 348.00 Million
Diagram Tasa de crecimiento anual compuesta (CAGR)
%
Diagram Jugadoras de los principales mercados
  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

>Mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África, por tipo (síndrome clínicamente aislado (CIS), EM remitente-recurrente (EMRR), EM progresiva primaria (EMPP), EM progresiva secundaria (EMSP)), tratamiento (medicamentos, terapia con células madre, fisioterapia , intercambio de plasma, otros), clase de fármaco (inmunomoduladores, inmunosupresores, interferones, otros), diagnóstico (imágenes por resonancia magnética (IRM), pruebas de estimulación eléctrica simple, punción lumbar, otros), vía de administración (oral, parenteral, otros), usuarios finales (hospitales, clínicas especializadas, atención domiciliaria, otros), canal de distribución (farmacia hospitalaria, farmacia minorista, farmacia en línea, otros) – Tendencias de la industria y pronóstico hasta 2029

Mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África

Análisis y tamaño del mercado

Según la Sociedad Nacional de Esclerosis Múltiple, la esclerosis múltiple afecta a aproximadamente 1 millón de personas en los Estados Unidos y a 2,3 millones de personas en todo el mundo. Cada año, aumenta el número de personas diagnosticadas con esclerosis múltiple, lo que hace necesario el desarrollo de nuevos medicamentos que sean más eficaces y tengan menos efectos secundarios. Los gobiernos y las organizaciones no gubernamentales de los países desarrollados y en desarrollo están aumentando sus esfuerzos para crear conciencia sobre la esclerosis múltiple y están destinando fondos importantes a la investigación y el desarrollo de medicamentos.

Data Bridge Market Research analiza que el mercado de tratamiento de la esclerosis múltiple se valoró en USD 235,54 millones en 2021 y se espera que alcance los USD 348,00 millones para 2029, registrando una CAGR del 5,00% durante el período de pronóstico de 2022 a 2029. El informe de mercado curado por el equipo de Data Bridge Market Research incluye un análisis experto en profundidad, epidemiología del paciente, análisis de la cartera, análisis de precios y marco regulatorio.

Alcance del informe y segmentación del mercado

Métrica del informe

Detalles

Período de pronóstico

2022 a 2029

Año base

2021

Años históricos

2020 (Personalizable para 2019 - 2014)

Unidades cuantitativas

Ingresos en millones de USD, volúmenes en unidades, precios en USD

Segmentos cubiertos

Por tipo (síndrome clínicamente aislado (CIS), esclerosis múltiple remitente-recurrente (RRMS), esclerosis múltiple progresiva primaria (PPMS), esclerosis múltiple progresiva secundaria (SPMS)), tratamiento (medicamentos, terapia con células madre, fisioterapia, intercambio de plasma, otros), clase de fármaco (inmunomoduladores, inmunosupresores, interferones, otros), diagnóstico (imágenes por resonancia magnética (MRI), pruebas de estimulación eléctrica simple, punción lumbar, otros), vía de administración (oral, parenteral, otros), usuarios finales (hospitales, clínicas especializadas, atención domiciliaria, otros), canal de distribución (farmacia hospitalaria, farmacia minorista, farmacia en línea, otros)

Países cubiertos

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Hikma Pharmaceuticals PLC (UK), Merck KGaA (Germany)

Market Opportunities

  • Increase in the number of emerging markets
  • Increase in the number of research and development activities
  • Rising investment for the development of advanced technologies
  • Surging drug approvals and launches

Market Definition

Multiple sclerosis (MS) is a chronic inflammatory immune-mediated disease that affects spinal cord and brain nerve cells, causing demyelination, axonal transection, and neurodegeneration. Injectable, oral, and infused medications, muscle relaxants, antidepressants, and physical therapy are some of the most widely utilized therapies. Interferon-beta and glatiramer acetate are injectable therapies that are given under the skin or into the muscle; oral medications include teriflunomide, dimethyl fumarate, and cladribine; and intravenous infusion treatments include ocrelizumab, alemtuzumab and natalizumab.

Middle East and Africa Multiple Sclerosis Treatment Market Dynamics

Drivers

  • Increasing prevalence of multiple sclerosis

The rising prevalence of multiple sclerosis is a primary driver of the multiple sclerosis treatment market's growth. Relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) are the types of multiple sclerosis and their high prevalence rate will influence the market dynamics during the forecast period.  

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of multiple sclerosis treatment market is the rising healthcare expenditure which helps in improving its infrastructure.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the multiple sclerosis treatment market. Additionally, high disposable income and increase in the development of innovative monoclonal antibodies, immunosuppressants, immunomodulators, and interferons will expand the multiple sclerosis treatment market. Along with this, rising geriatric population and continuously changing lifestyle will enhance the market's growth rate.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the multiple sclerosis treatment market growth. Along with this, rising drug approvals and launches will further propel the market’s growth rate.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will further provide beneficial opportunities for the growth of the multiple sclerosis treatment market during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment of multiple sclerosis will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the multiple sclerosis treatment market. Additionally, a decline in clinical visits due to COVID0-19 outbreak and lack of awareness among people will act as restrain and further impede the growth rate of market during the forecast period of 2022-2029.

This Middle East and Africa multiple sclerosis treatment market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the Middle East and Africa multiple sclerosis treatment market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Multiple sclerosis treatment market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

COVID-19 Impact on Middle East and Africa Multiple Sclerosis Treatment Market

Desde su aparición en diciembre de 2019, el virus COVID-19 se ha propagado a casi todos los países del planeta, lo que llevó a la Organización Mundial de la Salud (OMS) a declararlo una emergencia de salud pública. Debido a la crisis financiera y al retraso en la prestación de atención médica especializada al priorizar los tratamientos relacionados con el COVID-19, los sistemas de atención médica de todo el mundo se han visto gravemente afectados a raíz de la pandemia de coronavirus. Los pacientes no pudieron ver a sus controles por diversas razones, incluida la dificultad para acceder a un médico, el miedo a la transmisión de la infección, la incapacidad de continuar las terapias y los procedimientos esenciales debido a las restricciones de la pandemia. Tales consideraciones pueden tener un impacto negativo en el mercado de la esclerosis múltiple en Oriente Medio y África en los últimos meses.

Desarrollo reciente

  • En agosto de 2020, Novartis anunció el lanzamiento de Kesimpta (ofatumumab) con la aprobación de la Administración de Alimentos y Medicamentos de los Estados Unidos (FDA). Es la primera y única terapia dirigida a células B autoadministrada para las personas que padecen esclerosis múltiple recurrente. Kesimpta combina una potente eficacia con un perfil de seguridad aceptable y puede autoadministrarse en casa, llenando un vacío crítico en el tratamiento de las formas recidivantes de esclerosis múltiple (EMR).

Alcance del mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África

El mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África está segmentado en función del tipo, la clase de fármaco, el tratamiento, el diagnóstico, la vía de administración, los usuarios finales y el canal de distribución. El crecimiento entre estos segmentos le ayudará a analizar los escasos segmentos de crecimiento de las industrias y a proporcionar a los usuarios una valiosa descripción general del mercado y conocimientos del mercado para ayudarlos a tomar decisiones estratégicas para identificar las principales aplicaciones del mercado.

Tipo

  • Síndrome clínicamente aislado (CIS)
  • Esclerosis múltiple remitente-recurrente (EMRR)
  • Esclerosis múltiple progresiva primaria (EMPP)
  • Esclerosis múltiple progresiva secundaria (EMSP)

Tratamiento

  • Medicamentos
  • Terapias inyectables
  • Interferón beta
  • Acetato de glatiramer
  • Medicamentos orales
  • Fumarato de dimetilo
  • Teriflunomida
  • Cladribina
  • Tratamientos de infusión intravenosa
    • Ocrelizumab
    • Natalizumab
    • Alemtuzumab
    • Terapia con células madre
    • Fisioterapia
    • Intercambio de plasma
    • Otros

Clase de droga

  • Inmunomoduladores
  • Inmunosupresores
  • Interferones
  • Otros

Diagnóstico

Vía de administración

  • Oral
  • Parenteral
  • Otros

Usuarios finales

  • Hospitales
  • Clínicas de especialidades
  • Cuidado domiciliario
  • Otros

Canal de distribución

  • Farmacia hospitalaria
  • Farmacia minorista
  • Farmacia en línea
  • Otros

Análisis y perspectivas regionales del mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África

Se analiza el mercado de tratamiento de la esclerosis múltiple de Oriente Medio y África y se proporcionan información y tendencias del tamaño del mercado por país, tipo, tratamiento, clase de fármaco, diagnóstico, vía de administración, usuarios finales y canal de distribución como se mencionó anteriormente.

Los países cubiertos en el informe del mercado de tratamiento de la esclerosis múltiple en Medio Oriente y África son Arabia Saudita, Emiratos Árabes Unidos, Sudáfrica, Egipto, Israel, el resto de Medio Oriente y África (MEA) como parte de Medio Oriente y África (MEA).

Se espera que Sudáfrica crezca durante el período de pronóstico de 2022 a 2029 en la región de Medio Oriente y África debido a la creciente conciencia sobre la esclerosis múltiple y al aumento del gasto en atención médica en esta región.

La sección de países del informe también proporciona factores de impacto de mercado individuales y cambios en la regulación en el mercado a nivel nacional que afectan las tendencias actuales y futuras del mercado. Puntos de datos como análisis de la cadena de valor aguas abajo y aguas arriba, tendencias técnicas y análisis de las cinco fuerzas de Porter, estudios de casos son algunos de los indicadores utilizados para pronosticar el escenario del mercado para países individuales. Además, la presencia y disponibilidad de marcas de Medio Oriente y África y sus desafíos enfrentados debido a la competencia grande o escasa de las marcas locales y nacionales, el impacto de los aranceles nacionales y las rutas comerciales al proporcionar un análisis de pronóstico de los datos del país.   

Análisis del panorama competitivo y de la cuota de mercado del tratamiento de la esclerosis múltiple en Oriente Medio y África

El panorama competitivo del mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África proporciona detalles por competidor. Los detalles incluidos son una descripción general de la empresa, las finanzas de la empresa, los ingresos generados, el potencial de mercado, la inversión en investigación y desarrollo, las nuevas iniciativas de mercado, la presencia en Oriente Medio y África, los sitios e instalaciones de producción, las capacidades de producción, las fortalezas y debilidades de la empresa, el lanzamiento de productos, la amplitud y la extensión de los productos, el dominio de las aplicaciones. Los puntos de datos anteriores proporcionados solo están relacionados con el enfoque de las empresas en relación con el mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África.

Algunos de los principales actores que operan en el mercado de tratamiento de la esclerosis múltiple en Oriente Medio y África son:

  • F. Hoffmann-La Roche Ltd. (Suiza)
  • Mylan NV (Estados Unidos)
  • Teva Pharmaceutical Industries Ltd. (Irlanda)
  • Sanofi (Francia)
  • Pfizer Inc. (Estados Unidos)
  • GlaxoSmithKline plc (Reino Unido)
  • Novartis AG (Suiza)
  • Bayer AG (Alemania)
  • Eli Lilly and Company (Estados Unidos)
  • Merck KGaA (Alemania)
  • Hikma Pharmaceuticals PLC (Reino Unido)


SKU-

Obtenga acceso en línea al informe sobre la primera nube de inteligencia de mercado del mundo

  • Panel de análisis de datos interactivo
  • Panel de análisis de empresas para oportunidades con alto potencial de crecimiento
  • Acceso de analista de investigación para personalización y consultas
  • Análisis de la competencia con panel interactivo
  • Últimas noticias, actualizaciones y análisis de tendencias
  • Aproveche el poder del análisis de referencia para un seguimiento integral de la competencia
Solicitud de demostración

Tabla de contenido

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 DISEASE TYPE LIFELINE CURVE

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 SECONDARY SOURCES

2.11 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: REGULATIONS

5 MARKET OVERVIEW

5.1 DRIVERS

5.1.1 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS

5.1.2 EXTENSIVE RESEARCH AND DEVELOPMENT ACTIVITY IN MULTIPLE SCLEROSIS TREATMENT

5.1.3 RISING GOVERNMENT INITIATIVES

5.1.4 INCREASING NEED FOR BETTER MULTIPLE SCLEROSIS TREATMENT OPTIONS

5.2 RESTRAINTS

5.2.1 PATENT EXPIRY OF DRUGS

5.2.2 HIGH COST OF TREATMENT

5.3 OPPORTUNITIES

5.3.1 INCREASING AWARENESS FOR MULTIPLE SCLEROSIS TREATMENT

5.3.2 INTRODUCTION OF DISEASE-MODIFYING DRUGS

5.3.3 PRESENCE OF STRONG PIPELINE DRUGS

5.4 CHALLENGES

5.4.1 INCREASING SIDE EFFECT OF MULTIPLE SCLEROSIS MEDICATION

5.4.2 LIMITATIONS IN MULTIPLE SCLEROSIS THERAPY

6 COVID-19 IMPACT ON MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN HEALTHCARE INDUSTRY

6.1 OVERVIEW

6.2 PRICE IMPACT

6.3 IMPACT ON DEMAND

6.4 IMPACT ON SUPPLY CHAIN

6.5 STRATEGIC DECISIONS FOR MANUFACTURERS

6.6 CONCLUSION

7 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE

7.1 OVERVIEW

7.1 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS)

7.2 SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS)

7.3 PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS)

7.4 SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES)

8 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT

8.1 OVERVIEW

8.2 PREVENTIVE THERAPIES

8.2.1 ORAL MEDICATION

8.2.1.1 TECFIDERA

8.2.1.2 GILENYA

8.2.1.3 AUBAGIO

8.2.1.4 MAVENCLAD

8.2.1.5 MAYZENT

8.2.1.6 VUMERITY

8.2.1.7 OTHERS

8.2.2 INJECTABLE MEDICATION

8.2.2.1 INTERFERON BETA-1A

8.2.2.1.1 AVONEX

8.2.2.1.2 REBIF

8.2.2.1.3 OTHERS

8.2.2.2 GLATIRAMER ACETATE

8.2.2.2.1 COPAXONE

8.2.2.2.2 GLATOPA

8.2.2.2.3 OTHERS

8.2.2.3 INTERFERON BETA-1B

8.2.2.3.1 BETASERON

8.2.2.3.2 EXTAVIA

8.2.2.4 PLEGRIDY/PEGINTERFERON BETA-1A

8.2.2.5 CHEMOTHERAPY DRUG

8.2.2.6 MONOCLONAL ANTIBODIES

8.2.3 INFUSED MEDICATION

8.2.3.1 TYSABRI

8.2.3.2 OCREVUS

8.2.3.3 LEMTRADA

8.2.3.4 MITOXANTRONE

8.2.3.5 NOVANTRONE

8.2.3.6 OTHERS

8.2.4 HAEMATOPOIETIC STEM CELL TRANSPLANTATION (HSCT)

8.3 ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS

8.3.1 CORTICOSTEROIDS

8.3.1.1 ORAL PREDNISONE

8.3.1.2 METHYLPREDNISOLONE

8.3.1.3 DEXAMETHASONE

8.3.1.4 PREDNISOLONE

8.3.1.5 BETAMETHASONE

8.3.1.6 OTHERS

8.3.2 IMMUNOSUPPRESSANTS

8.3.2.1 AZATHIOPRINE

8.3.2.2 CYCLOPHOSPHAMIDE

8.3.2.3 METHOTREXATE

8.3.2.4 MITOXANTRONE

8.3.2.5 OTHERS

8.3.3 ADRENOCORTICOTROPIC HORMONE

8.3.4 PLASMAPHERESIS

8.3.5 INTRAVENOUS IMMUNOGLOBULIN

8.3.6 OTHERS

8.4 SYMPTOMATIC THERAPIES

8.4.1.1 MUSCLE RELAXANTS

8.4.1.1.1 LIORESAL

8.4.1.1.2 ZANAFLEX

8.4.1.1.3 OTHERS

8.4.1.2 FATIGUE MEDICATIONS

8.4.1.2.1 GOCOVRI

8.4.1.2.2 OSMOLEX

8.4.1.2.3 PROVIGIL

8.4.1.2.4 RITALIN

8.4.1.2.5 OTHERS

8.4.1.3 PHYSIOTHERAPY

8.4.1.4 LAXATIVES

9 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE

9.1 OVERVIEW

9.2 BRANDED

9.2.1 TECFIDERA

9.2.2 GILENYA

9.2.3 AUBAGIO

9.2.4 AVONEX

9.2.5 TYSABRI

9.2.6 REBIF

9.2.7 COPAXONE

9.2.8 8 BETASERON

9.2.9 AMPYRA/FAMPYRA

9.2.10 OTHERS

9.3 GENERIC

10 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 ORAL

10.3 PARENTERAL

10.3.1 INTRAVENOUS

10.3.2 SUBCUTANEOUS

10.3.3 OTHERS

11 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.3 HOMECARE

11.4 SPECIALTY CENTERS

11.5 OTHERS

12 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL

12.1 OVERVIEW

12.2 RETAIL SALES

12.2.1 RETAIL PHARMACY

12.2.2 HOSPITAL PHARMACY

12.3 DIRECT TENDER

13 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY GEOGRAPHY

13.1 MIDDLE EAST & AFRICA

13.1.1 SAUDI ARABIA

13.1.2 SOUTH AFRICA

13.1.3 UAE

13.1.4 ISRAEL

13.1.5 KUWAIT

13.1.6 EGYPT

13.1.7 REST OF MIDDLE EAST & AFRICA

14 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, COMPANY LANDSCAPE

14.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

15 SWOT

16 COMPANY PROFILES

16.1 BIOGEN

16.1.1 COMPANY SNAPSHOT

16.1.2 REVENUE ANALYSIS

16.1.3 COMPANY SHARE ANALYSIS

16.1.4 PRODUCT PORTFOLIO

16.1.5 RECENT DEVELOPMENT

16.2 NOVARTIS AG

16.2.1 COMPANY SNAPSHOT

16.2.2 REVENUE ANALYSIS

16.2.3 COMPANY SHARE ANALYSIS

16.2.4 PRODUCT PORTFOLIO

16.2.5 RECENT DEVELOPMENTS

16.3 GENZYME CORPORATION (A SUBSIDIARY OF SANOFI)

16.3.1 COMPANY SNAPSHOT

16.3.2 REVENUE ANALYSIS

16.3.3 COMPANY SHARE ANALYSIS

16.3.4 PRODUCT PORTFOLIO

16.3.5 RECENT DEVELOPMENTS

16.4 MERCK KGAA

16.4.1 COMPANY SNAPSHOT

16.4.2 REVENUE ANALYSIS

16.4.3 COMPANY SHARE ANALYSIS

16.4.4 PRODUCT PORTFOLIO

16.4.5 RECENT DEVELOPMENTS

16.5 TEVA PHARMACEUTICALS USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICALS INDUSTRIES LTD.)

16.5.1 COMPANY SNAPSHOT

16.5.2 REVENUE ANALYSIS

16.5.3 COMPANY SHARE ANALYSIS

16.5.4 PRODUCT PORTFOLIO

16.5.5 RECENT DEVELOPMENTS

16.6 F. HOFFMANN-LA ROCHE LTD

16.6.1 COMPANY SNAPSHOT

16.6.2 REVENUE ANALYSIS

16.6.3 PRODUCT PORTFOLIO

16.6.4 RECENT DEVELOPMENTS

16.7 ACORDA THERAPEUTICS, INC.

16.7.1 COMPANY SNAPSHOT

16.7.2 REVENUE ANALYSIS

16.7.3 PRODUCT PORTFOLIO

16.7.4 1.7.4 RECENT DEVELOPMENT

16.8 ADAMAS PHARMACEUTICALS, INC.

16.8.1 COMPANY SNAPSHOT

16.8.2 REVENUE ANALYSIS

16.8.3 PRODUCT PORTFOLIO

16.8.4 RECENT DEVELOPMENT

16.9 AMNEAL PHARMACEUTICALS LLC

16.9.1 COMPANY SNAPSHOT

16.9.2 REVENUE ANALYSIS

16.9.3 PRODUCT PORTFOLIO

16.9.4 RECENT DEVELOPMENT

16.1 BAYER AG

16.10.1 COMPANY SNAPSHOT

16.10.2 1.10.2REVENUE ANALYSIS

16.10.3 PRODUCT PORTFOLIO

16.10.4 RECENT DEVELOPMENT

16.11 CELGENE CORPORATION (A SUBSIDIARY OF BRISTOL-MYERS SQUIBB COMPANY)

16.11.1 COMPANY SNAPSHOT

16.11.2 REVENUE ANALYSIS

16.11.3 PRODUCT PORTFOLIO

16.11.4 RECENT DEVELOPMENTS

16.12 HIKMA PHARMACEUTICALS PLC

16.12.1 COMPANY SNAPSHOT

16.12.2 REVENUE ANALYSIS

16.12.3 PRODUCT PORTFOLIO

16.12.4 RECENT DEVELOPMENTS

16.13 LANNETT

16.13.1 COMPANY SNAPSHOT

16.13.2 REVENUE ANALYSIS

16.13.3 PRODUCT PORTFOLIO

16.13.4 RECENT DEVELOPMENT

16.14 MALLINCKRODT

16.14.1 COMPANY SNAPSHOT

16.14.2 REVENUE ANALYSIS

16.14.3 PRODUCT PORTFOLIO

16.14.4 RECENT DEVELOPMENTS

16.15 MYLAN N.V.

16.15.1 COMPANY SNAPSHOT

16.15.2 REVENUE ANALYSIS

16.15.3 PRODUCT PORTFOLIO

16.15.4 RECENT DEVELOPMENTS

16.16 PAR PHARMACEUTICAL (A SUBSIDIARY OF ENDO INTERNATIONAL PLC)

16.16.1 COMPANY SNAPSHOT

16.16.2 REVENUE ANALYSIS

16.16.3 PRODUCT PORTFOLIO

16.16.4 RECENT DEVELOPMENTS

16.17 PFIZER INC.

16.17.1 COMPANY SNAPSHOT

16.17.2 REVENUE ANALYSIS

16.17.3 PRODUCT PORTFOLIO

16.17.4 RECENT DEVELOPMENTS

16.18 ZYDUS PHARMACEUTICALS, INC. (A SUBSIDIARY OF ZYDUS CADILA)

16.18.1 COMPANY SNAPSHOT

16.18.2 REVENUE ANALYSIS

16.18.3 PRODUCT PORTFOLIO

16.18.4 RECENT DEVELOPMENT

17 QUESTIONNAIRE

18 RELATED REPORTS

Lista de Tablas

LIST OF TABLES

TABLE 1 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, PIPELINE ANALYSIS

TABLE 2 MULTIPLE SCLEROSIS DRUGS IN PIPELINE

TABLE 3 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 1 MIDDLE EAST AND AFRICA RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 2 MIDDLE EAST AND AFRICA SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS (SPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 3 MIDDLE EAST AND AFRICA PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS (PPMS) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 4 MIDDLE EAST AND AFRICA SEVERE RELAPSING–REMITTING MULTIPLE SCLEROSIS (RES) IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 5 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 6 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 7 MIDDLE EAST AND AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 8 MIDDLE EAST AND AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 9 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 10 MIDDLE EAST AND AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 11 MIDDLE EAST AND AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 12 MIDDLE EAST AND AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 13 MIDDLE EAST AND AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 14 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 15 MIDDLE EAST AND AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 16 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 17 MIDDLE EAST AND AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 18 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 19 MIDDLE EAST AND AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 20 MIDDLE EAST AND AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 21 MIDDLE EAST AND AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 22 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 23 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 24 MIDDLE EAST AND AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 25 MIDDLE EAST AND AFRICA GENERIC IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 26 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 27 MIDDLE EAST AND AFRICA ORAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 28 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY RUOTE OF ADMINISTRATION, 2018-2027 (USD MILLION)

TABLE 30 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 31 MIDDLE EAST AND AFRICA HOSPITAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 32 MIDDLE EAST AND AFRICA HOMECARE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 33 MIDDLE EAST AND AFRICA SPECIALTY CENTERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 34 MIDDLE EAST AND AFRICA OTHERS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 35 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 36 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 37 MIDDLE EAST AND AFRICA RETAIL SALES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 38 MIDDLE EAST AND AFRICA DIRECT TENDER IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY REGION, 2018-2027 (USD MILLION)

TABLE 39 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY COUNTRY, 2018-2027 (USD MILLION)

TABLE 40 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 41 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 42 MIDDLE EAST & AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 43 MIDDLE EAST & AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 44 MIDDLE EAST & AFRICA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 45 MIDDLE EAST & AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 46 MIDDLE EAST & AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 47 MIDDLE EAST & AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 48 MIDDLE EAST & AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 49 MIDDLE EAST & AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 50 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 51 MIDDLE EAST & AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 52 MIDDLE EAST & AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 53 MIDDLE EAST & AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 54 MIDDLE EAST & AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 55 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 56 MIDDLE EAST & AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 57 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 58 MIDDLE EAST & AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 59 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 60 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 61 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 62 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 63 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 64 SAUDI ARABIA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 65 SAUDI ARABIA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 66 SAUDI ARABIA INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 67 SAUDI ARABIA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 68 SAUDI ARABIA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 69 SAUDI ARABIA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 70 SAUDI ARABIA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 71 SAUDI ARABIA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 72 SAUDI ARABIA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 73 SAUDI ARABIA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 74 SAUDI ARABIA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 75 SAUDI ARABIA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 76 SAUDI ARABIA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 77 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 78 SAUDI ARABIA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 79 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 80 SAUDI ARABIA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 81 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 82 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 83 SAUDI ARABIA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 84 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 85 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 86 SOUTH AFRICA PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 87 SOUTH AFRICA ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 88 SOUTH AFRICA INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 89 SOUTH AFRICA GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 90 SOUTH AFRICA INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 91 SOUTH AFRICA INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 92 SOUTH AFRICA ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 93 SOUTH AFRICA CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 94 SOUTH AFRICA IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 95 SOUTH AFRICA SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 96 SOUTH AFRICA MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 97 SOUTH AFRICA FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 98 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 99 SOUTH AFRICA BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 100 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 101 SOUTH AFRICA PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 102 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 103 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 104 SOUTH AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 105 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 106 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 107 UAE PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 108 UAE ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 109 UAE INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 110 UAE INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 111 UAE GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 112 UAE INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 113 UAE INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 114 UAE ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 115 UAE CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 116 UAE IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 117 UAE SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 118 UAE MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 119 UAE FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 120 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 121 UAE BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 122 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 123 UAE PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 124 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 125 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 126 UAE MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 127 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 128 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 129 ISRAEL PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 130 ISRAEL ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 131 ISRAEL INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 132 ISRAEL INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 133 ISRAEL GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 134 ISRAEL INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 135 ISRAEL INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 136 ISRAEL ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 137 ISRAEL CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 138 ISRAEL IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 139 ISRAEL SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 140 ISRAEL MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 141 ISRAEL FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 142 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 143 ISRAEL BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 144 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 145 ISRAEL PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 146 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 147 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 148 ISRAEL MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 149 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 150 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 151 KUWAIT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 152 KUWAIT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 153 KUWAIT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 154 KUWAIT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 155 KUWAIT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 156 KUWAIT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 157 KUWAIT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 158 KUWAIT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 159 KUWAIT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 160 KUWAIT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 161 KUWAIT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 162 KUWAIT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 163 KUWAIT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 164 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 165 KUWAIT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 166 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 167 KUWAIT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 168 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 169 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 170 KUWAIT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 171 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

TABLE 172 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 173 EGYPT PREVENTIVE THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 174 EGYPT ORAL MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 175 EGYPT INJECTABLE MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 176 EGYPT INTERFERON BETA-1A IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 177 EGYPT GLATIRAMER ACETATE IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 178 EGYPT INTERFERON BETA-1B IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 179 EGYPT INFUSED MEDICATION IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 180 EGYPT ABORTIVE THERAPIES/TREATMENT OF ACUTE EXACERBATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 181 EGYPT CORTICOSTEROIDS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 182 EGYPT IMMUNOSUPPRESSANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 183 EGYPT SYMPTOMATIC THERAPIES IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 184 EGYPT MUSCLE RELAXANTS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 185 EGYPT FATIGUE MEDICATIONS IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 186 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2018-2027 (USD MILLION)

TABLE 187 EGYPT BRANDED IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY D, 2018-202RUG TYPE7 (USD MILLION)

TABLE 188 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 189 EGYPT PARENTERAL IN MULTIPLE SCLEROSIS TREATMENT MARKET, BY TREATMENT, 2018-2027 (USD MILLION)

TABLE 190 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2018-2027 (USD MILLION)

TABLE 191 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 192 EGYPT MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018-2027 (USD MILLION)

TABLE 193 REST OF MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISEASE TYPE, 2018-2027 (USD MILLION)

 

Lista de figuras

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 2 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 8 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SEGMENTATION

FIGURE 10 INCREASING PREVALENCE OF MULTIPLE SCLEROSIS AND RISING GOVERNMENT INITIATIVES ARE EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN THE FORECAST PERIOD OF 2020 TO 2027

FIGURE 11 RELAPSING–REMITTING MULTIPLE SCLEROSIS (RRMS) SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET IN 2020 & 2027

FIGURE 12 PIPELINE ANALYSIS

FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET

FIGURE 14 MULTIPLE SCLEROSIS PREVALENCE

FIGURE 15 MULTIPLE SCLEROSIS PREVALENCE BY GENDER

FIGURE 16 PIPELINE BY DEVELOPMENT PHASE, 2019 VERSUS 2018

FIGURE 17 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019

FIGURE 18 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, 2019-2027 (USD MILLION)

FIGURE 19 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, CAGR (2020-2027)

FIGURE 20 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISEASE TYPE, LIFELINE CURVE

FIGURE 21 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019

FIGURE 22 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, 2019-2027 (USD MILLION)

FIGURE 23 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, CAGR (2020-2027)

FIGURE 24 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TREATMENT, LIFELINE CURVE

FIGURE 25 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, 2019

FIGURE 26 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DRUG TYPE, 2019-2027 (USD MILLION)

FIGURE 27 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, CAGR (2020-2027)

FIGURE 28 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 29 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2019

FIGURE 30 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2019-2027 (USD MILLION)

FIGURE 31 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2027)

FIGURE 32 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 33 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, 2019

FIGURE 34 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY END USER, 2019-2027 (USD MILLION)

FIGURE 35 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, CAGR (2020-2027)

FIGURE 36 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 37 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2019

FIGURE 38 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2019-2027 (USD MILLION)

FIGURE 39 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2027)

FIGURE 40 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 41 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: SNAPSHOT (2019)

FIGURE 42 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019)

FIGURE 43 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2020 & 2027)

FIGURE 44 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY COUNTRY (2019 & 2027)

FIGURE 45 MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: BY TYPE (2020-2027)

FIGURE 46 MIDDLE EAST AND AFRICA MULTIPLE SCLEROSIS TREATMENT MARKET: COMPANY SHARE 2019 (%)

 

Ver información detallada Right Arrow

Metodología de investigación

La recopilación de datos y el análisis del año base se realizan utilizando módulos de recopilación de datos con muestras de gran tamaño. La etapa incluye la obtención de información de mercado o datos relacionados a través de varias fuentes y estrategias. Incluye el examen y la planificación de todos los datos adquiridos del pasado con antelación. Asimismo, abarca el examen de las inconsistencias de información observadas en diferentes fuentes de información. Los datos de mercado se analizan y estiman utilizando modelos estadísticos y coherentes de mercado. Además, el análisis de la participación de mercado y el análisis de tendencias clave son los principales factores de éxito en el informe de mercado. Para obtener más información, solicite una llamada de un analista o envíe su consulta.

La metodología de investigación clave utilizada por el equipo de investigación de DBMR es la triangulación de datos, que implica la extracción de datos, el análisis del impacto de las variables de datos en el mercado y la validación primaria (experto en la industria). Los modelos de datos incluyen cuadrícula de posicionamiento de proveedores, análisis de línea de tiempo de mercado, descripción general y guía del mercado, cuadrícula de posicionamiento de la empresa, análisis de patentes, análisis de precios, análisis de participación de mercado de la empresa, estándares de medición, análisis global versus regional y de participación de proveedores. Para obtener más información sobre la metodología de investigación, envíe una consulta para hablar con nuestros expertos de la industria.

Personalización disponible

Data Bridge Market Research es líder en investigación formativa avanzada. Nos enorgullecemos de brindar servicios a nuestros clientes existentes y nuevos con datos y análisis que coinciden y se adaptan a sus objetivos. El informe se puede personalizar para incluir análisis de tendencias de precios de marcas objetivo, comprensión del mercado de países adicionales (solicite la lista de países), datos de resultados de ensayos clínicos, revisión de literatura, análisis de mercado renovado y base de productos. El análisis de mercado de competidores objetivo se puede analizar desde análisis basados ​​en tecnología hasta estrategias de cartera de mercado. Podemos agregar tantos competidores sobre los que necesite datos en el formato y estilo de datos que esté buscando. Nuestro equipo de analistas también puede proporcionarle datos en archivos de Excel sin procesar, tablas dinámicas (libro de datos) o puede ayudarlo a crear presentaciones a partir de los conjuntos de datos disponibles en el informe.

Preguntas frecuentes

The market value for the Middle East and Africa Multiple Sclerosis Treatment Market is expected USD 348.00 million by 2029.
The Middle East and Africa Multiple Sclerosis Treatment Market is to grow at a CAGR of 5.00% during the forecast period of 2022 to 2029
The major players operating in the Middle East and Africa Multiple Sclerosis Treatment Market are F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (US), Teva Pharmaceutical Industries Ltd.(Ireland), Sanofi (France), Pfizer Inc. (US), GlaxoSmithKline plc (UK), Novartis AG (Switzerland), Bayer AG (Germany), Hikma Pharmaceuticals PLC (UK), Merck KGaA (Germany).
The major countries covered in the Middle East and Africa Multiple Sclerosis Treatment Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.